NVAX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 66933 min ago

@ $5.28

Išleistas: 13 kov. 2024 @ 20:02

Grąža: -22.55%

Ankstesnis signalas: kov. 13 - 19:12

Ankstesnis signalas: Pirkimas

Grąža: 1.36 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs...

Stats
Šios dienos apimtis	3.01M
Vidutinė apimtis	7.13M
Rinkos kapitalizacija	572.41M
EPS	$0 ( 2024-02-28 )
Kita pelno data	( $-1.040 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.760
ATR14	$0.00800 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Trizzino John	Buy	144 000	Restricted Stock Units
2024-03-01	O'hara Elaine	Buy	120 000	Restricted Stock Units
2024-03-01	Kelly James Patrick	Buy	176 000	Restricted Stock Units
2024-03-01	Dubovsky Filip	Buy	144 000	Restricted Stock Units
2024-03-01	Casey Mark J	Buy	12 000	Restricted Stock Units

INSIDER POWER
62.99
Last 99 transactions
Buy: 1 952 927 \| Sell: 481 828

Tūris Koreliacija

Ilgas: -0.13 (neutral)

Trumpas: -0.71 (moderate negative)

Signal:(49.895) Neutral

Novavax Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Novavax Inc Koreliacija - Valiuta/Žaliavos

0.00
( neutral )

0.35
( neutral )

0.00
( neutral )

-0.05
( neutral )

Novavax Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$983.71M
Bruto pelnas:	$704.24M (71.59 %)
EPS:	$-5.41

FY	2023
Pajamos:	$983.71M
Bruto pelnas:	$704.24M (71.59 %)
EPS:	$-5.41

FY	2022
Pajamos:	$1.60B
Bruto pelnas:	$696.31M (43.55 %)
EPS:	$-8.42

FY	2021
Pajamos:	$1.15B
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-23.44

Financial Reports:

No articles found.

Novavax Inc

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.